Fig. 8

ACBD3 mutation in various tumors of TCGA. A The alteration type and frequency. Among the many alteration types of ACBD3, “Amplification” was the most common type in patients with breast invasive carcinoma (BRCA) (9.22% alteration frequency) and liver hepatocellular carcinoma (LIHC) (5.38% alteration frequency). B The 3D structure of ACBD3 protein. C The number, sites, and types of the ACBD3 genetic alteration. “Missense Mutation” was the most dominant type of mutation. The alteration of R484Q/* and R516W in GOLD-2 is able to lead to the missense mutation of ACBD3. D–F The correlation between ACBD3 alternation and clinical outcomes in different tumors. For BRCA, cases with ACBD3 alternation had a worse prognosis in both progression-free survival and disease-specific survival. Patients with LIHC with ACBD3 alternation had a better prognosis in overall survival